Erk, S
Mohnke, S
Ripke, S
Lett, T A
Veer, I M
Wackerhagen, C
Grimm, O
Romanczuk-Seiferth, N
Degenhardt, F
Tost, H
Mattheisen, M
Mühleisen, T W
Charlet, K
Skarabis, N
Kiefer, F
Cichon, S
Witt, S H
Nöthen, M M
Rietschel, M
Heinz, A
Meyer-Lindenberg, A
Walter, H
Article History
Received: 10 November 2016
Accepted: 13 November 2016
First Online: 10 January 2017
Competing interests
: AML received consultancy fees from Astra Zeneca, Elsevier, F Hoffmann-La Roche, Gerson Lehrman Group, Lundbeck foundation, Outcome Europe Sárl, Outcome Sciences, Roche Pharma, Servier International and Thieme Verlag, and lecture fees—including the travel fees—from Abbott, Astra Zeneca, Aula Médica Congresos, BASF, Groupo Ferrer International, Janssen-Cilag, Lilly Deutschland, LVR Klinikum Düsseldorf, Servier Deutschland and Otsuka Pharmaceuticals. HW received a speaker honorarium from Servier. The remaining authors declare no conflict of interest.